

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June 2013

PART - I					
Sr. No.	Particulars	Three months ended 30/06/2013 Unaudited	Preceding three months ended 31/03/2013 Audited	Corresponding three months ended 30/06/2012 Unaudited	(Rs in Lacs) Previous year ended 31/03/2013 Audited
1	Income from Operation				
	(a) Net Sales/Income from Operations (Net of Excise Duty)	8070.79	11450.11	7159.48	32742.72
	(b) Other Operating Income	0.83	6.13	3.17	24.51
	Total Income From Operation (Net)	8,071.62	11,456.24	7,162.65	32,767.23
2	Expenditure				
	a) Cost of Material Consumed	4850.39	7361.87	3050.69	18508.5
	b) Purchase of Stock In Trade				
	c) Change in Inventories of Finished Goods, Work In Progress and Stock In trade	-372.68	-479.22	2125.86	901.36
	d) Employee Benefit Expenses	472.09	372.49	595.10	2128.12
	e) Depreciation and Amortisation Expenses	456.05	705.52	446.05	2299.58
	f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately)	2623.15	4161.98	2688.27	12606.68
	Total Expenses	8029.00	12122.64	8905.97	36444.24
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	42.62	(666.40)	(1,743.32)	(3,677.01)
4	Other Income	0.00	0.00	0.00	0.00
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	42.62	(666.40)	(1,743.32)	(3,677.01)
6	Finance costs	1418.31	1199.00	1201.44	5584.68
7	Profit/(Loss) from ordinary activities after finance costs but before Exceptional items (5 - 6)	(1,375.68)	(1,865.40)	(2,944.76)	(9,261.69)
8	Exceptional items	5227.10	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	3,851.42	(1,865.40)	(2,944.76)	(9,261.69)
10	Tax Expenses	-1228.62	1296.93	72.29	1522.05
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	5,080.04	(3,162.33)	(3,017.05)	(10,783.74)
12	Extraordinary items (net of tax expense Lakhs)	0.00			0.00
13	Net Profit / (Loss) for the period (11 + 12)	5,080.04	(3,162.33)	(3,017.05)	(10,783.74)
14	Share of profit / (loss) of associates*				
15	Minority Interest *				
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	5,080.04	(3,162.33)	(3,017.05)	(10,783.74)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2586.68	2586.68	2586.68	2586.68
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				19078.14
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):				
	(a) Basic	19.64	(12.23)	(11.66)	(41.69)
	(b) Diluted	19.64	(12.23)	(11.66)	(41.69)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):				
	(a) Basic	19.64	(12.23)	(11.66)	(41.69)
	(b) Diluted	19.64	(12.23)	(11.66)	(41.69)

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act 1956.

Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.

PART -II

A PARTICULARS OF SHAREHOLDING					
1	Public Shareholding				
	-Number of Shares	79,44,924	79,44,924	79,44,924	79,44,924
	-Percentage of shareholding	30.71%	30.71%	30.71%	30.71%
2	Promoters and Promoter Group Shareholding **				
	a) Pledged/Encumbered				
	-Number of shares	1,79,21,907	1,79,21,907	73,78,799	1,79,21,907
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	41.17%	100.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	60.20%	60.29%	28.53%	60.29%
	b) Non-encumbered				
	-Number of shares			1,06,43,109	
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)			58.83%	
	-Percentage of Shares (as a % of the total share capital of the Company)			40.76%	
B Detail of Investor Complaint					
		3 months ended (30.06.2013)			
Pending at the beginning of the quarter		0			
Received during the quarter		3			
Disposed of during the quarter		3			
Remaining unresolved at the end of the quarter		0			

NOTES :

- The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 13th August 2013.
- The unaudited financial results of the subsidiary companies have been consolidated.
- The Company's one subsidiary company has advised that in view of their major expansion plan scheduled for the current year by adding three IV fluid manufacturing units, no income tax liability is envisaged during the current financial year hence no provision for taxes is required to be made.
- The Company is engaged in the Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17).
- The previous year/period have been regrouped/rearranged wherever found necessary.
- The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com). The key standalone financial results are given below:

Sr. No.	Particulars	Quarter Ended		Year Ended	
		Unaudited	Audited	Unaudited	Audited
		30.06.2013	31.03.2013	30.06.2012	31.03.2013
1	Income from operations & other income	5,024.40	5,169.10	4,858.93	18,735.29
2	Profit/Loss before tax	(1,412.74)	(1,591.91)	(3,002.34)	(8,169.88)
3	Profit/Loss after tax	(1,407.74)	(1,791.48)	(3,052.34)	(8,519.53)

For and on behalf of Board of Directors

Place: Indore
Date: 13th August 2013

 Vinod Kumar Gupta
Managing Director

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June 2013

PART - I					(Rs in Lacs)
Sr. No.	Particulars	Three months ended 30/06/2013 Unaudited	Preceding three months ended 31/03/2013 Audited	Corresponding three months ended 30/06/2012 Unaudited	Previous year ended 31/03/2013 Audited
1	Income from Operation				
	(a) Net Sales/Income from Operations of Excise Duty) (Net	5024.12	5186.88	4857.39	18721.55
	(b) Other Operating Income	0.29	2.28	1.54	13.74
	Total Income From Operation (Net)	5,024.40	5,189.16	4,858.93	18,735.29
2	Expenditure				
	a) Consumption of Material Consumed	2982.30	4622.22	1473.45	10018.2
	b) Purchase of Stock In Trade				
	c) Change in Inventories of Finished Goods, Work in Progress and Stock In trade	-449.98	-598.47	2262.56	1720.37
	d) Employee Benefit Expenses	400.83	214.63	552.14	1736.48
	e) Depreciation and Amortisation Expenses	439.71	443.84	430.00	1733.84
	f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately	1771.93	1371.81	2068.34	7473.95
	Total Expenses	5144.79	6054.03	6786.49	22682.84
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(120.39)	(864.87)	(1,927.56)	(3,947.55)
4	Other Income		0.00		0.00
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(120.39)	(864.87)	(1,927.56)	(3,947.55)
6	Finance costs	1292.35	727.04	1074.78	4222.44
7	Profit after Interest but before Exceptional items (5-6)	(1,412.74)	(1,591.91)	(3,002.34)	(8,169.99)
8	Exceptional items		0.00		0.00
9	Profit / (Loss) from ordinary activities before tax	(1,412.74)	(1,591.91)	(3,002.34)	(8,169.99)
10	Tax Expenses	85.00	199.54	50.00	349.54
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(1,497.74)	(1,791.45)	(3,052.34)	(8,519.53)
12	Extraordinary items (net of tax expense) Lakhs)				
13	Net Profit / (Loss) for the period (11 + 12)	(1,497.74)	(1,791.45)	(3,052.34)	(8,519.53)
14	Share of profit / (loss) of associates*				
15	Minority interest *				
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(1,497.74)	(1,791.45)	(3,052.34)	(8,519.53)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2586.68	2586.68	2586.68	2586.68
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				16848.8
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):				
	(a) Basic	(5.79)	(6.93)	(11.80)	(32.94)
	(b) Diluted	(5.79)	(6.93)	(11.80)	(32.94)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):				
	(a) Basic	(5.79)	(6.93)	(11.80)	(32.94)
	(b) Diluted	(5.79)	(6.93)	(11.80)	(32.94)

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956.

Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.

PART -II**A PARTICULARS OF SHAREHOLDING**

1	Public Shareholding				
	-No. of Shares	79,44,924	79,44,924	79,44,924	79,44,924
	-Percentage of shareholding	30.71%	30.71%	30.71%	30.71%
2	Promoters and Promoter Group Shareholding **				
	a) Pledged/Encumbered				
	-No. of shares	1,79,21,907	1,79,21,907	73,78,799	1,79,21,907
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	41.17%	100.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	69.29%	69.29%	28.53%	69.29%
	b) Non-encumbered				
	-No. of shares			1,05,43,108	
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)			58.83%	
	-Percentage of Shares (as a % of the total share capital of the Company)			40.76%	
B	Detail of Investor Compliant	3 months ended (30.06.2013)			
	Pending at the beginning of the quarter				
	Received during the quarter				
	Disposed of during the quarter				
	Remaining unresolved at the end of the quarter				

NOTES :

- 1 The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 13th August 2013.
- 2 The Company is engaged in the Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17).
- 3 The previous year/period have been regrouped/rearranged wherever found necessary.
- 4 The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com). The key standalone financial results are given below:

Place: Indore
Date: 13th August 2013

For and on behalf of Board of Directors

 Vinod Kumar Gupta
Managing Director